In a report released yesterday, Sean Lavin from BTIG reiterated a Hold rating on Edwards Lifesciences (NYSE: EW). The company’s shares closed yesterday at $111.84.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 11.2% and a 58.2% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Obalon Therapeutics Inc.
Edwards Lifesciences has an analyst consensus of Strong Buy, with a price target consensus of $123.50.
Based on Edwards Lifesciences’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $884 million and quarterly net profit of $230 million. In comparison, last year the company earned revenue of $697 million and had a net profit of $143 million.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Patrick Verguet, the CVP, Europe of EW sold 11,500 shares for a total of $1,283,775.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the design, development, manufacture, and markets products to treat stage cardiovascular disease. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient’s heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Critical Care portfolio products include pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.